Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135563 | 0.79 | F2 (0.53) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL9738285 | 0.79 | F2 (0.53) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL16042071 | 0.76 | F2 (0.50) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL17137206 | 0.76 | KMT2A (0.51) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL12377380 | 0.72 | GAA (0.52) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL5138891 | 0.72 | F2 (0.59) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL9385131 | 0.71 | F2 (0.48) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL17318141 | 0.70 | LMNA (0.50) | GAALMNAF2PRSS1PRSS2 | |
| SCHEMBL82589 | 0.70 | MAPT (0.65) | GAALMNAALDH1A1MEN1KMT2A | |
| SCHEMBL663730 | 0.70 | CYP2C19 (0.59) | GAALMNAF2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180338-B1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | BOEHRINGER INGELHEIM INT (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-3180338-B1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | BOEHRINGER INGELHEIM INT (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-3180338-A1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | Boehringer Ingelheim International GmbH (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-9422312-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422312-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422312-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| WO-2016023789-A1 | AZABENZIMIDAZOLE DERIVATIVES AS AMP PROTEIN KINASE AGONISTES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039846-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039846-A1 | AZABENZIMIDAZOLE DERIVATIVES | PRKAB1, PRKAB2, PRKAG1 | GAA 747/4885LMNA 2521/4885F2 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.